Healthcare
Specifically, the report indicated that biotechnology companies drove the healthcare industry to make up almost two-thirds of IPO activity in the second quarter of 2020.
Gilead Sciences set the price of the only approved treatment for COVID-19, remdesivir, at $390 per vial, which for most patients receiving a 5-day treatment using six vials, would come to $2,340 per patient.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.
PRESS RELEASES